Bao Pharma Buys Back 52,100 H-Shares, Treasury Stock Rises to 147,300 Shares

Bulletin Express07-06

Shanghai Bao Pharmaceuticals Co., Ltd. (“Bao Pharma”) reported a share buyback on 6 July 2026, purchasing 52,100 H-shares on the Hong Kong Stock Exchange for an aggregate HK$0.97 million. The shares were repurchased at prices ranging between HK$18.19 and HK$18.68, implying a volume-weighted average cost of HK$18.65 per share.

The transaction reduced the company’s issued share capital (excluding treasury shares) by 0.03378%, from 154.23 million to 154.18 million shares. Concurrently, treasury shares increased from 95,200 to 147,300, while total issued shares remained unchanged at 154.33 million. All 52,100 repurchased shares have been retained as treasury stock; none have been cancelled.

Since securing its repurchase mandate on 26 May 2026—authorising purchases of up to 15.43 million shares—Bao Pharma has acquired 147,300 shares, representing 0.10% of the company’s issued share base at the mandate date. A 30-day moratorium on new share issues or treasury share sales is in effect until 5 August 2026, in line with Hong Kong listing rules.

Management affirmed that the buybacks comply with the Hong Kong Stock Exchange’s Main Board Listing Rules and all applicable legal and regulatory requirements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1113048495?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-06 19:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1113048495","market":"hk","top_or_hot":-1,"title":"Bao Pharma Buys Back 52,100 H-Shares, Treasury Stock Rises to 147,300 Shares","media":"Bulletin Express","content":"<p>Shanghai Bao Pharmaceuticals Co., Ltd. (“Bao Pharma”) reported a share buyback on 6 July 2026, purchasing 52,100 H-shares on the Hong Kong Stock Exchange for an aggregate HK$0.97 million. The shares were repurchased at prices ranging between HK$18.19 and HK$18.68, implying a volume-weighted average cost of HK$18.65 per share.</p>\n<p>The transaction reduced the company’s issued share capital (excluding treasury shares) by 0.03378%, from 154.23 million to 154.18 million shares. Concurrently, treasury shares increased from 95,200 to 147,300, while total issued shares remained unchanged at 154.33 million. All 52,100 repurchased shares have been retained as treasury stock; none have been cancelled.</p>\n<p>Since securing its repurchase mandate on 26 May 2026—authorising purchases of up to 15.43 million shares—Bao Pharma has acquired 147,300 shares, representing 0.10% of the company’s issued share base at the mandate date. A 30-day moratorium on new share issues or treasury share sales is in effect until 5 August 2026, in line with Hong Kong listing rules.</p>\n<p>Management affirmed that the buybacks comply with the Hong Kong Stock Exchange’s Main Board Listing Rules and all applicable legal and regulatory requirements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bao Pharma Buys Back 52,100 H-Shares, Treasury Stock Rises to 147,300 Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBao Pharma Buys Back 52,100 H-Shares, Treasury Stock Rises to 147,300 Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-06 19:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Bao Pharmaceuticals Co., Ltd. (“Bao Pharma”) reported a share buyback on 6 July 2026, purchasing 52,100 H-shares on the Hong Kong Stock Exchange for an aggregate HK$0.97 million. The shares were repurchased at prices ranging between HK$18.19 and HK$18.68, implying a volume-weighted average cost of HK$18.65 per share.</p>\n<p>The transaction reduced the company’s issued share capital (excluding treasury shares) by 0.03378%, from 154.23 million to 154.18 million shares. Concurrently, treasury shares increased from 95,200 to 147,300, while total issued shares remained unchanged at 154.33 million. All 52,100 repurchased shares have been retained as treasury stock; none have been cancelled.</p>\n<p>Since securing its repurchase mandate on 26 May 2026—authorising purchases of up to 15.43 million shares—Bao Pharma has acquired 147,300 shares, representing 0.10% of the company’s issued share base at the mandate date. A 30-day moratorium on new share issues or treasury share sales is in effect until 5 August 2026, in line with Hong Kong listing rules.</p>\n<p>Management affirmed that the buybacks comply with the Hong Kong Stock Exchange’s Main Board Listing Rules and all applicable legal and regulatory requirements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02659","symbol_name":"宝济药业-B","start_time":0,"source_url":"","article_id":"1113048495","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1113048495","pubTimestamp":1783336024,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Bao Pharmaceuticals Co., Ltd. (“Bao Pharma”) reported a share buyback on 6 July 2026, purchasing 52,100 H-shares on the Hong Kong Stock Exchange for an aggregate HK$0.97 million. The shares...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02659":"宝济药业-B"},"translate_title":"宝药业回购5.21万股H股库存股升至14.73万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02659":1},"content_text":"Shanghai Bao Pharmaceuticals Co., Ltd. (“Bao Pharma”) reported a share buyback on 6 July 2026, purchasing 52,100 H-shares on the Hong Kong Stock Exchange for an aggregate HK$0.97 million. The shares were repurchased at prices ranging between HK$18.19 and HK$18.68, implying a volume-weighted average cost of HK$18.65 per share.\nThe transaction reduced the company’s issued share capital (excluding treasury shares) by 0.03378%, from 154.23 million to 154.18 million shares. Concurrently, treasury shares increased from 95,200 to 147,300, while total issued shares remained unchanged at 154.33 million. All 52,100 repurchased shares have been retained as treasury stock; none have been cancelled.\nSince securing its repurchase mandate on 26 May 2026—authorising purchases of up to 15.43 million shares—Bao Pharma has acquired 147,300 shares, representing 0.10% of the company’s issued share base at the mandate date. A 30-day moratorium on new share issues or treasury share sales is in effect until 5 August 2026, in line with Hong Kong listing rules.\nManagement affirmed that the buybacks comply with the Hong Kong Stock Exchange’s Main Board Listing Rules and all applicable legal and regulatory requirements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1113048495","isCrawlerRequest":true}